UOC
PEARW

UBS O'Connor’s Pear Therapeutics, Inc. Warrant PEARW Stock Holding History

UBS O'Connor’s Portfolio PEARW Stock Details PEARW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-83,330
Closed -$76K – 1077
2021
Q3 		$76K Hold
83,330
– – ﹤0.01% 858
2021
Q2 		$120K Hold
83,330
– – ﹤0.01% 801
2021
Q1 		$69K Buy
+83,330
New +$81.2K ﹤0.01% 780

Other funds holding PEARW

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return
PSAMP
P. Schoenfeld Asset Management (PSAM) New York $184M AUM 97.09% 1-Year Est. Return
OCAM
Owl Creek Asset Management New York $1.38B AUM 59.67% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.94% 1-Year Est. Return
KCM
Kingstown Capital Management New York $30.4M AUM 3.71% 1-Year Est. Return
AGC
Angelo Gordon & Co New York $1.06B AUM 47.95% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AR
Advisory Research Chicago, Illinois $813M AUM 36.71% 1-Year Est. Return

UBS O'Connor's PEARW Position: Q4 2021 in Review

UBS O'Connor sold out of Pear Therapeutics, Inc. Warrant (PEARW) in Q4 2021, closing a stake of 83,330 shares — an estimated $76K sold.

UBS O'Connor first reported a position in PEARW in Q1 2021 and held it in 3 quarters. The position peaked at $120K in Q2 2021. 44 funds tracked by Wall St. Rank hold PEARW as of Q4 2021.

  • UBS O'Connor reported no remaining Pear Therapeutics, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
  • UBS O'Connor sold 83,330 Pear Therapeutics, Inc. Warrant shares in Q4 2021, an estimated $76K.
  • UBS O'Connor first reported a position in Pear Therapeutics, Inc. Warrant in Q1 2021 and held it in 3 quarters.
  • UBS O'Connor's Pear Therapeutics, Inc. Warrant position peaked at $120K in Q2 2021.
  • 44 funds tracked by Wall St. Rank held Pear Therapeutics, Inc. Warrant as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.